Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy

BioDrugs

Volumn 28, Issue 2, 2014, Pages 133-144

  Mezzano, Veronica ^a   Giavina Bianchi, Pedro ^a   Picard, Matthieu ^a   Caiado, Joana ^a   Castells, Mariana ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CETUXIMAB; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; INFLIXIMAB; MONOCLONAL ANTIBODY; PACLITAXEL; RITUXIMAB; TENIPOSIDE; TRASTUZUMAB;

ANAPHYLAXIS; CHEMOTHERAPY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; MAST CELL; PREMEDICATION; PRIORITY JOURNAL; RAPID DRUG DESENSITIZATION; REVIEW; ADVERSE EFFECTS; DESENSITIZATION; IMMUNOLOGY; PROCEDURES; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; TIME FACTORS;

EID: 84897046499     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0066-x     Document Type: Review

References (87)

1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
2. World Health Organization Glossary of Terms (2007). http://www.who.int/ medicines/areas/quality-safety/safety-efficacy/Annex1GlossaryofTerms.pdf. Accessed 18 Aug 2013.
3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6. (Pubitemid 38608590)
4. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin North Am. 2004;24(3):345-56. (Pubitemid 38887342)
5. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(3 Suppl):S67-73.
6. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-93, e1-22.
7. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol. 2006;117(2):391-7. (Pubitemid 43190153)
8. Campbell RL, Hagan JB, Manivannan V, Decker WW, Kanthala AR, Bellolio MF, et al. Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network Criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012;129(3): 748-52.
9. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125(3):569-74, 74 e1-74 e7.
10. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3): 451-63. (Pubitemid 44247540)
11. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-80.
12. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259-66.
13. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;123(6):1262-7, e1.
14. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68(7):853-61.
15. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol. 2011;41(4):1004-13.
16. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365-78. (Pubitemid 46674486)
17. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80.
18. Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. J Clin Immunol. 2012;32(1):150-60.
19. MacGlashan D Jr. Subthreshold desensitization of human basophils re-capitulates the loss of Syk and FcepsilonRI expression characterized by other methods of desensitization. Clin Exp Allergy. 2012;42(7):1060-70.
20. MacGlashan DW Jr, Ishmael S, MacDonald SM, Langdon JM, Arm JP, Sloane DE. Induced loss of Syk in human basophils by non-IgE-dependent stimuli. J Immunol. 2008;180(6):4208-17.
21. MacGlashan DW Jr. Relationship between spleen tyrosine kinase and phosphatidylinositol 5′ phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol. 2007;119(3):626-33.
22. Macglashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol. 2004;114(6):1317-24. (Pubitemid 39575884)
23. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94(5):575-80. (Pubitemid 40712782)
24. Groner B, Hartmann C, Wels W. Therapeutic antibodies. Curr Mol Med. 2004;4(5):539-47. (Pubitemid 38961197)
25. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220-33.
26. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012;8(1): 43-52 (quiz 53-4).
27. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62(1):209-43. (Pubitemid 34169431)
28. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7(1):55-63.
29. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther. 2011;13(Suppl 1):S2.
30. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American Gastroenterological Association Consensus Development Conference on the use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology. 2007;133(1):312-39. (Pubitemid 47031141)
31. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol. 2007;7(5):393-403. (Pubitemid 47415282)
32. Soriano ER, Galarza-Maldonado C, Cardiel MH, Pons-Estel BA, Massardo L, Caballero-Uribe CV, et al. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology (Oxford). 2008;47(7):1097-9. (Pubitemid 351865942)
33. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59(6):785-93. (Pubitemid 351847560)
34. Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39(11):2153-6.
35. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33. (Pubitemid 351650318)
36. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34(9): 1864-8. (Pubitemid 350067647)
37. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol. 2012;23(Suppl 10):x313-9.
38. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66-73. (Pubitemid 29523413)
39. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10(5):345-56. (Pubitemid 40647253)
40. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med. 2008;358(11):1109-17. (Pubitemid 351398485)
41. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393-9. (Pubitemid 41502850)
42. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824-9. (Pubitemid 40255508)
43. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95(2):370-6. (Pubitemid 39445874)
44. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am. 2010;94(4): 835-52, xiii.
45. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24(3):253-62. (Pubitemid 36584220)
46. National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1.2013. http://www.nccn.org/ professionals/physician-gls/pdf/ovarian.pdf. Accessed 18 Aug 2013.
47. Navo M, Kunthur A, Badell ML, Coffer LW 2nd, Markman M, Brown J, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103(2):608-13. (Pubitemid 44602175)
48. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol. 2006;6(4):271-7. (Pubitemid 44510183)
49. Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1):36-41.
50. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601-9.
51. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104(3):640-3. (Pubitemid 41022823)
52. Zanotti KM, Markman M. Prevention and management of anti-neoplastic- induced hypersensitivity reactions. Drug Saf. 2001;24(10):767-79. (Pubitemid 32848355)
53. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53(1):121-2. (Pubitemid 24136913)
54. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84(3):378-82. (Pubitemid 34211861)
55. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;21(24):4611-4. (Pubitemid 46594035)
56. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007;197(2):199 e1-4 (discussion e4-5).
57. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs. 2010;2010:207084. doi:10.1155/2010/207084.
58. National Comprehensive Cancer Network. Breast cancer, version 2.2013. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed 18 Aug 2013.
59. National Comprehensive Cancer Network. Non-small cell lung cancer, version 2.2013. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed 18 Aug 2013.
60. Markman M. Taxol: an important new drug in the management of epithelial ovarian cancer. Yale J Biol Med. 1991;64(6):583-90.
61. Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst. 1995;87(9):676-81.
62. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006;17(5):735-49.
63. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654-66. (Pubitemid 24379653)
64. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84(3):420-5. (Pubitemid 34211869)
65. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263-8. (Pubitemid 20195638)
66. Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag. 2005;1(2):107-14.
67. Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, Disilvestro P, et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol. 2006;100(1):149-51. (Pubitemid 41815065)
68. Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol. 2010;20(2):170-1.
69. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs. 2009;20(1):1-6.
70. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14(9):1430-7. (Pubitemid 37185291)
71. Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, et al. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol. 2008;18(5):566-70.
72. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2): 238-49.
73. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303-9.
74. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-26. (Pubitemid 38500969)
75. Soyer OU, Aytac S, Tuncer A, Cetin M, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol. 2009;123(4):895-9.
76. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45(4):492-8.
77. de Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M. Hypersensitivity reactions to etoposide: a report of three cases and review of the literature. Am J Clin Oncol. 1994;17(5):387-9. (Pubitemid 24298940)
78. Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer. 2002;86(1):12-3. (Pubitemid 34146333)
79. Lindsay H, Gaynon P. Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer. 2012;59(4):765.
80. Anonymous. A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc. 2011;32(1):79.
81. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatininduced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129(2):443-7.
82. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001;82(3):550-8. (Pubitemid 32826458)
83. Markman M, Hsieh F, Zanotti K, Webster K, Peterson G, Kulp B, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol. 2004;130(1): 25-8. (Pubitemid 38161244)
84. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102-5. (Pubitemid 30036342)
85. Schwartz JR. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly? J Oncol Pharm Pract. 2012;18(2): 250-6.
86. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15(9):3149-55. (Pubitemid 27377507)
87. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102(2): 155-60.